Expanded Access Policy

Expanded Access Policy for 4A10 (T-ALL Program)

Allterum Therapeutics is developing 4A10 as an investigational therapy for patients with T-cell Acute Lymphoblastic Leukemia (T-ALL). At this stage of development, 4A10 is available only through participation in clinical trials.

Because clinical development is ongoing and supply is limited, Allterum Therapeutics is not offering Expanded Access (compassionate use) to 4A10 outside of clinical trials at this time.

We will review this policy periodically as additional safety, efficacy, and manufacturing data become available. Any updates will be posted on this page.

For information about active or upcoming clinical studies, please refer to: ClinicalTrials.gov

Contact Us

What can we help you with today?
We'd love to hear from you.

Submit